Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial

American Journal of Respiratory and Critical Care Medicine

Volumn 197, Issue 3, 2018, Pages 356-363

  Vancheri, Carlo ⁱ   Kreuter, Michael ^a   Richeldi, Luca ^b   Ryerson, Christopher J ^c   Valeyre, Dominique ^d   Grutters, Jan C ^e,f   Wiebe, Sabrina ^g   Stansen, Wibke ^g   Quaresma, Manuel ^a,g   Stowasser, Susanne ^g   Wuyts, Wim A ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d AVICENNE HOSPITAL   (France)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ UNIVERSITY OF CATANIA   (Italy)

Author keywords

Clinical trial; Drug therapy; Interstitial lung diseases; Myofibroblasts; Resulting in excessive deposition of extracellular matrix; The destruction of the lung architecture (2)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NINTEDANIB; PIRFENIDONE; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TROUGH CONCENTRATION; UPPER ABDOMINAL PAIN; VOMITING; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; MORTALITY; PATIENT SAFETY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; PATIENT SAFETY; PYRIDONES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85045263730     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201706-1301OC     Document Type: Article

References (16)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183: 788-824.
2. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012; 380:680-688.
3. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV (nintedanib) prescribing information [accessed 2017 Jun 9.]. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing1Information/PIs/Ofev/ofev. pdf.
4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370: 2071-2082.
5. Genentech USA. Inc. ESBRIET (pirfenidone) prescribing information [accessed 2017 Jun 9]. Available from: http://www.gene.com/download/pdf/esbriet_prescribing.pdf.
6. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-2092.
7. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al.; ATS, ERS, JRS, ALAT. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192: e3-e19. [Published erratum appears in Am J Respir Crit Care Med 2015;192:644.]
8. Wuyts WA, Antoniou KM, Borensztajn K, Costabel U, Cottin V, Crestani B, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014;2:933-942.
9. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-1445.
10. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-b-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 2014;58:13-19.
11. Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1382-1392.
12. Taniguchi H, Ogura T, Inoue Y, Akimoto M, Azuma A. Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF [abstract]. Eur Respir J 2016;48: PA2089.
13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
14. Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015;16:116.
15. Mason WR, Nathan SD, Zibrak JD, Padilla ML, Gilberg F, Petzinger U, et al. Time-to-event analysis of common adverse events with pirfenidone in patients with IPF: a pooled analysis of three phase III clinical trials [abstract]. Am J Respir Crit Care Med 2017;195: A6798.
16. Flaherty KR, Sussman R, Pesci A, Nunes H, Acosta O, Petzinger U, et al. Safety of the combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from an interim analysis after 12 weeks [astract]. Am J Respir Crit Care Med 2017;195:A5398.